AC Immune SA
Symbol: ACIU (NASDAQ)
3.22
▲ (14.59%) 0.410
Company Description:
AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The Company has one segment. The Company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
Key Stats
- Today's Open: $2.81
- Today's High: $3.374
- Today's Low: $2.815
- Today's Volume: 588.65K
- Yesterday Close: $2.81
- Yesterday High: $2.92
- Yesterday Low: $2.7
- Yesterday Volume: 158.76K
- Last Min Volume: 200
- Last Min High: $3.22
- Last Min Low: $3.22
- Last Min VWAP: $3.22
Company Profile
- Name: AC Immune SA
- Website: https://www.acimmune.com
- Listed Date: 2016-09-23
- Location: ,
- Market Status: Active
- CIK Number: 0001651625
- SIC Code:
- SIC description:
- Market Cap: $282.69M
- Round Lot: 100
- Outstanding Shares: 100.60M
- Asset Type: CS
RECENT FILINGS FOR ACIU
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-03 | 144 | View |
| 2025-09-12 | 144 | View |
| 2025-09-04 | 6-K | View |
| 2025-08-05 | 6-K | View |
| 2025-07-24 | 144 | View |
| 2025-06-20 | 6-K | View |
| 2025-06-11 | 6-K | View |
| 2025-05-19 | 6-K | View |
| 2025-04-30 | 6-K | View |
| 2025-03-13 | 6-K | View |
| 2025-03-13 | 20-F | View |
| 2024-12-18 | 6-K | View |
| 2024-12-13 | SC 13G/A | View |
| 2024-12-10 | 6-K | View |
| 2024-11-14 | SC 13G/A | View |
| 2024-11-14 | 6-K | View |
| 2024-11-05 | 6-K | View |
| 2024-09-27 | 144 | View |
| 2024-09-19 | 6-K | View |
| 2024-09-18 | 144 | View |
Latest News on ACIU